Modifying antibiotic treatment strategies in the face of pertussis surge associated to erythromycin resistance in China

Wei Shi,Qinghong Meng,Yahong Hu,Kaihu Yao
DOI: https://doi.org/10.1016/j.jinf.2024.106174
IF: 28.2
2024-05-07
Journal of Infection
Abstract:Highlights • Macrolides should NOT continue to be the first choice for the empirical treatment of pertussis in China. • Trimethoprim-sulfamethoxazole is recommended for current pertussis treatment in China. • Beta-lactam drugs are effective for most ERBP infections and can be used as an alternative therapy. • Research on other pertussis treatments should be promoted immediately in China.
infectious diseases
What problem does this paper attempt to address?